Read by QxMD icon Read

Clinical Colorectal Cancer

Aabra Ahmed, Ahmed Tahseen, Elizabeth England, Katrine Wolfe, Michael Simhachalam, Travis Homan, Jenna Sitenga, Ryan W Walters, Peter T Silberstein
BACKGROUND: Colon cancer is the third most frequent cancer diagnosis, and primary payer status has been shown to be associated with treatment modalities and survival in cancer patients. The goal of our study was to determine the between-insurance differences in survival in patients with clinical stage III colon cancer using data from the National Cancer Database (NCDB). MATERIALS AND METHODS: We identified 130,998 patients with clinical stage III colon cancer in the NCDB diagnosed from 2004 to 2012...
September 13, 2018: Clinical Colorectal Cancer
Ieva Kurilova, Regina G H Beets-Tan, Jessica Flynn, Mithat Gönen, Gary Ulaner, Elena N Petre, F Edward Boas, Etay Ziv, Hooman Yarmohammadi, Elisabeth G Klompenhouwer, Andrea Cercek, Nancy A Kemeny, Constantinos T Sofocleous
INTRODUCTION: The purpose of this study was to identify predictors of overall (OS) and liver progression-free survival (LPFS) following Yttrium-90 radioembolization (RAE) of heavily pretreated patients with colorectal cancer liver metastases (CLM), as well as to create and validate a predictive nomogram for OS. MATERIALS AND METHODS: Metabolic, anatomic, laboratory, pathologic, genetic, primary disease, and procedure-related factors, as well as pre- and post-RAE therapies in 103 patients with CLM treated with RAE from September 15, 2009 to March 21, 2017 were analyzed...
September 13, 2018: Clinical Colorectal Cancer
Manuela Vasconcelos Castro Sales, Claudia K Suemoto, Daniel Apolinario, ValeriaT Serrao, Celi S Andrade, David M Conceição, Edson Amaro, Brian Alvarez Ribeiro de Melo, Rachel P Riechelmann
PURPOSE: Chemotherapy-related cognitive impairment can occur in cancer survivors after treatment, especially those patients who have undergone chemotherapy for breast cancer. The frequency and to what extent such toxicity develops in colorectal cancer (CRC) survivors is unknown. The present prospective study evaluated the effects of adjuvant chemotherapy on the cognitive performance of patients with localized CRC compared with a control group who had not undergone chemotherapy. PATIENTS AND METHODS: Consecutive patients with localized stage II and III CRC completed neuropsychological assessments, self-reported cognitive complaint questionnaires, and depressive symptom evaluations before starting fluoropyrimidine-based adjuvant chemotherapy and after 12 months...
September 13, 2018: Clinical Colorectal Cancer
Ryuma Tokunaga, Shu Cao, Madiha Naseem, Jae Ho Lo, Francesca Battaglin, Alberto Puccini, Martin D Berger, Shivani Soni, Joshua Millstein, Wu Zhang, Sebastian Stintzing, Fotios Loupakis, Chiara Cremolini, Volker Heinemann, Alfredo Falcone, Heinz-Josef Lenz
BACKGROUND: Adenosine has an immunosuppressive and angiogenic modulation of the tumor microenvironment. The present study explored the efficacy of single nucleotide polymorphisms (SNPs) in adenosine-related molecules for patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. PATIENTS AND METHODS: We analyzed genomic DNA extracted from 451 samples from 3 independent cohorts: a discovery cohort of 107 patients treated with FOLFIRI (5-fluorouracil, leucovorin, oxaliplatin, irinotecan) plus bevacizumab in FIRE-3 (ClinicalTrials...
September 13, 2018: Clinical Colorectal Cancer
Bradford J Kim, Guillaume Passot
No abstract text is available yet for this article.
August 30, 2018: Clinical Colorectal Cancer
Sang Kyu Cho, Joel W Hay, Afsaneh Barzi
BACKGROUND: Regorafenib and TAS-102 are standard treatment options in refractory metastatic colorectal cancer based on improvement in overall survival by 6 and 8 weeks, respectively, when compared with best supportive care alone (BSC). Given the small incremental clinical benefit, we evaluated their cost-effectiveness from a United States payer's perspective. MATERIALS AND METHODS: A Markov model was constructed to compare costs and effectiveness of regorafenib, TAS-102, and BSC...
August 24, 2018: Clinical Colorectal Cancer
Yu Sunakawa, Dongyun Yang, Shu Cao, Wu Zhang, Miriana Moran, Stephanie H Astrow, Jack Hsiang, Craig Stephens, Akihito Tsuji, Takehiro Takahashi, Hiroaki Tanioka, Yuji Negoro, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Tetsuya Eto, Masashi Fujii, Wataru Ichikawa, Heinz-Josef Lenz
BACKGROUND: Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-related genes affect the NLR remain unclear. PATIENTS AND METHODS: In 77 patients with KRAS exon2 wild-type mCRC from prospective trials of first-line chemotherapy with cetuximab, expression levels of 354 immune-related genes were measured in tissue samples obtained from all patients by the HTG EdgeSeq Oncology Biomarker Panel...
August 23, 2018: Clinical Colorectal Cancer
Ahmed Mokhtar, Thomas Arnason, Daniel Gaston, Weei-Yuarn Huang, Heather MacKenzie, Rayan Al-Hazmi, Nadine Vaninetti, Barna Tugwell, Daniel Rayson
BACKGROUND: Approximately 30% of neuroendocrine tumors (NETs) present with secretory syndromes or develop one during the course of the disease. Cushing syndrome caused by a gastrointestinal tract NET is rare, with limited published information. We describe a patient with florid Cushing syndrome due to ectopic adrenocorticotropic hormone (ACTH) from a NET of colonic origin. A literature review was conducted to describe the spectrum of this clinical and pathologic entity as reported in the scientific literature...
August 11, 2018: Clinical Colorectal Cancer
Bin Ma, Peng Gao, Yongxi Song, Xuanzhang Huang, Hongchi Wang, Qingzhou Xu, Shan Zhao, Zhenning Wang
BACKGROUND: To assess whether preoperative short-course radiotherapy (PSRT) could be the treatment of choice compared to preoperative long-course chemoradiotherapy (PLCRT) METHODS: The PubMed, Embase, and Web of Science Databases were searched to conduct a systematic review and meta-analysis. Perioperative and survival outcomes between PSRT and PLCRT were selected as end points for our meta-analysis. In addition, health-related quality-of-life outcomes were also systematically reviewed between PSRT and PLCRT...
August 11, 2018: Clinical Colorectal Cancer
Narikazu Boku, Shun Yamamoto
Continuation of anti-angiogenic agents beyond progression in second-line therapy is recognized as a standard of care for patients with metastatic colorectal cancer, and there are 3 options based on the results of the phase III trials: bevacizumab (ML18147 trial), ramucirumab (RAISE trial), and aflibercept (VELOUR trial). However, the eligibility criteria of these three trials differed, and there are no established biomarkers for selecting the optimal agent. In a collaborative study of the RAISE trial, it was reported that vascular endothelial growth factor (VEGF)-D may be a predictive marker for remucirumab, which can prevent binding of VEGF-D to VEGF receptor, and establishment of the standard method for assessing VEGF-D is eagerly awaited...
August 1, 2018: Clinical Colorectal Cancer
Gabriel Glockzin, Florian Zeman, Roland S Croner, Alfred Königsrainer, Jörg Pelz, Michael A Ströhlein, Beate Rau, Dirk Arnold, Michael Koller, Hans J Schlitt, Pompiliu Piso
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) as parts of an interdisciplinary treatment concept including systemic chemotherapy can improve survival of selected patients with peritoneal metastatic colorectal cancer (pmCRC). Nevertheless, the sequence of the therapeutic options is still a matter of debate. Thus, the COMBATAC (COMBined Anticancer Treatment of Advanced Colorectal cancer) trial was conducted to evaluate a combined treatment regimen consisting of preoperative systemic polychemotherapy + cetuximab followed by CRS + HIPEC and postoperative systemic polychemotherapy + cetuximab...
July 31, 2018: Clinical Colorectal Cancer
Kenji Tsuchihashi, Mamoru Ito, Toshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Taito Esaki, Akitaka Makiyama, Tadamichi Denda, Hironaga Satake, Takeshi Suto, Naotoshi Sugimoto, Kenji Katsumata, Toshiaki Ishikawa, Tomomi Kashiwada, Eiji Oki, Yoshito Komatsu, Hiroyuki Okuyama, Daisuke Sakai, Hideki Ueno, Takao Tamura, Kimihiro Yamashita, Junji Kishimoto, Yasuhiro Shimada, Eishi Baba
BACKGROUND: Assessment of patient factors is essential for selecting later-line chemotherapy in patients with metastatic colorectal cancer (mCRC). The efficacy, prognosis, and safety of each treatment regimen according to nutritional and inflammatory status still remain to be elucidated. PATIENTS AND METHODS: A total of 550 patients with mCRC who were registered in the REGOTAS study (Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study, UMIN 000020416) and treated with trifluridine/tipiracil (TFTD) or regorafenib as a later-line therapy were retrospectively stratified according to the modified Glasgow Prognostic Score (mGPS), which divided patients into mGPS 0 to 2 by serum albumin and C-reactive protein, and compared...
July 29, 2018: Clinical Colorectal Cancer
Takayuki Yoshino, Kentaro Yamazaki, Eiji Shinozaki, Yoshito Komatsu, Tomohiro Nishina, Hideo Baba, Akihito Tsuji, Yasushi Tsuji, Kensei Yamaguchi, Naotoshi Sugimoto, Tadamichi Denda, Kei Muro, Tetsuji Takayama, Taito Esaki, Yasuo Hamamoto, Toshikazu Moriwaki, Yasuhiro Shimada, Masahiro Goto, Norisuke Nakayama, Hirofumi Fujii, Takanori Tanase, Atsushi Ohtsu
BACKGROUND: High thymidine kinase 1 (TK1) activity increases the incorporation of trifluridine (FTD) into DNA; thus, FTD antitumor activity is likely to increase in patients with high tumoral TK1 activity. To date, no established predictive biomarker to indicate the clinical benefit of FTD/tipiracil (TPI) has been identified. We aimed to determine the relationship between TK1 expression and FTD/TPI efficacy in refractory metastatic colorectal cancer. PATIENTS AND METHODS: Individual patient data from 2 randomized placebo-controlled trials were analyzed...
July 26, 2018: Clinical Colorectal Cancer
Sunil W Dutta, Clayton E Alonso, Taylor C Jones, Mark R Waddle, Einsley-Marie Janowski, Daniel M Trifiletti
INTRODUCTION: The purpose of this study was to compare the utilization, pathologic response, and overall survival (OS) between long-course neoadjuvant chemoradiation (LC-CRT) and short-course neoadjuvant radiation (SC-RT) in the treatment of non-metastatic rectal cancer. METHODS AND MATERIALS: Retrospective data was obtained from the National Cancer Database (NCDB) for patients diagnosed with clinical stage II or III (limited to T3, any N or T1-2, N1-2) rectal cancer between 2004 and 2014 (28,193 patients)...
July 26, 2018: Clinical Colorectal Cancer
Stefanie Noepel-Duennebacke, Dirk Arnold, Jan Hertel, Andrea Tannapfel, Axel Hinke, Susanna Hegewisch-Becker, Anke Reinacher-Schick
INTRODUCTION: Numerous trials have examined the prognostic and predictive value of localization of the primary tumor (LPT) in metastastic colorectal cancer, there is limited information about the predictive value of LPT on different maintenance strategies. MATERIALS AND METHODS: We analyzed progression-free survival (PFS)/overall survival (OS) on maintenance therapy according to LPT and mutational subgroups (BRAF/RAS) in patients from the AIO (Arbeitsgemeinschaft Internistische Onkologie) 0207 trial...
July 25, 2018: Clinical Colorectal Cancer
Haider H Samawi, Yaling Yin, Caroline H Speers, Winson Y Cheung
BACKGROUND: Women have been shown to experience longer overall survival after colorectal cancer (CRC) diagnosis than men even after adjusting for disease stage and management. However, the etiology of this observation is not well understood, and the impact of non-CRC health conditions on survival has not been described. We aimed to evaluate the prognostic role of sex on CRC-specific outcomes. PATIENTS AND METHODS: All patients who underwent primary resection of stage I to III CRC from 2001 to 2005, and who were referred to cancer centers in a large, representative Canadian province were reviewed...
July 21, 2018: Clinical Colorectal Cancer
Marta Schirripa, Giuseppe Pasqualetti, Riccardo Giampieri, Mario Scartozzi, Sara Lonardi, Laura Rumanò, Francesca Bergamo, Silvia Stragliotto, Sabina Murgioni, Giulia Alberti, Mario Domenico Rizzato, Alessandra Anna Prete, Marco Puzzoni, Valeria Pusceddu, Pina Ziranu, Fabiana Pani, Stefano Mariotti, Vittorina Zagonel, Fabio Monzani, Fotios Loupakis
BACKGROUND: The impact of free triiodothyronine (FT3 )/free thyroxine (FT4 ) ratio on survival in hospitalized geriatric patients was recently described. Up today, there are no data regarding the prognostic role of FT3 /FT4 ratio in patients with advanced cancer. We evaluated the impact of FT3 /FT4 ratio on survival in patients with refractory colorectal cancer (CRC) treated with regorafenib. METHODS: Patients with metastatic CRC treated with regorafenib with available clinical data and baseline measurement of FT3 , FT4 , and thyroid-stimulating hormone (TSH) were considered eligible...
September 2018: Clinical Colorectal Cancer
(no author information available yet)
No abstract text is available yet for this article.
September 2018: Clinical Colorectal Cancer
Michael Davidson, Catherine Cafferkey, Emily Frances Goode, Kyriakos Kouvelakis, Daniel Hughes, Pablo Reguera, Eleftheria Kalaitzaki, Clare Peckitt, Sheela Rao, David Watkins, Ian Chau, David Cunningham, Naureen Starling
BACKGROUND: Although progress has been made in the molecular stratification of esophagogastric adenocarcinoma, the outlook for advanced disease remains poor. The present evaluation of over 500 patients treated at a single European high-volume tertiary center during a 6-year period gives important information on current and developing "real-world" treatment patterns and outcomes. RESULTS: The overall survival for the whole cohort was 11.5 months, with a range of treatments used in first-, second-, and third-line settings...
September 2018: Clinical Colorectal Cancer
Margaret M Lee, Andrew MacKinlay, Christine Semira, Christine Schieber, Antonio Jose Jimeno Yepes, Belinda Lee, Rachel Wong, Chathurika K H Hettiarachchige, Natalie Gunn, Jeanne Tie, Hui-Li Wong, Iain Skinner, Ian T Jones, James Keck, Suzanne Kosmider, Ben Tran, Kathryn Field, Peter Gibbs
BACKGROUND: Multiple studies have defined the prognostic and potential predictive significance of the primary tumor side in metastatic colorectal cancer (CRC). However, the currently available data for early-stage disease are limited and inconsistent. MATERIALS AND METHODS: We explored the clinicopathologic, treatment, and outcome data from a multisite Australian CRC registry from 2003 to 2016. Tumors at and distal to the splenic flexure were considered a left primary (LP)...
September 2018: Clinical Colorectal Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"